Executive Medical Director / Head of US Medical
Posted on: 22 Oct 2021
Weston, MA
Job Description
Job Description
The US Alzheimer's Disease Medical Lead will be accountable for all the US launch activities related to Alzheimer's Disease in collaboration with the other members of the Alzheimer's Disease Medical team and the cross functional partners. This position leads and oversees all the US launch and post-launch activities for Alzheimer's Disease. Reporting to the VP-US and Global Alzheimer Medical, and is responsible for developing and implementing the launch strategy, including overseeing the Alzheimer's Disease medical science liaison team and medical directors.
The US Medical Lead represents Medical in the Alzheimer's Disease US Leadership Team (US ADLT) and is an ad hoc member of the US Leadership Team (USLT) and in that capacity, has frequent interactions with Executive management.
Biogen’s priority is to continue to foster and enable a diverse and inclusive workforce – representing age, gender, sexual identity, race, ethnicity, Veterans, and people with disabilities – that reflects the communities where we operate and the patients who we serve.
This individual is responsible for developing the strategy in alignment with the cross-functional partners and ensuring that the metrics and goals are met across the US AD medical organization.
Key Accountabilities:
Accountable for the development of the US Launch and post-launch strategy and tactical plan, including developing measurable metrics
Sits on the US ADLT and Alzheimer's Disease Medical Leadership team and is the key point of contact for internal US-related interactions with senior management and externally with the key medical experts and other key stakeholders
Accountable for ensuring production of highest quality local data generation plan in alignment with the cross-functional stakeholders and overall Alzheimer's Disease Medical strategy
Accountable for attracting, retaining, developing and supervising a team of US medical affairs Alzheimer's Disease experts both in the Medical Director office and MSL team as business needs require
Qualifications
???????Who You Are
You enjoy leading teams and collaborating cross-functionally. You are accomplished in setting and communicating strategy as well as communicating a clear vision for tactical execution.
Required Skills
Advanced degree (MD, PhD, PharmD) ideally with training in neurology
10+ years in pharmaceutical industry with experience in leading US Drug Launch activities in Medical affairs (neurology preferred)
Experience managing and developing large medical organizations
Demonstrated leadership capabilities including the ability to solve problems effectively in a highly collaborative matrix environment
Preferred Skills
US Medical Launch experience desired
Alzheimer's Disease or Neuroscience experience strongly preferred
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
